Attempts to treat cancer with drugs that target mutated proteins have met with mixed success. By screening for compounds that alter the phenotype of glioblastoma cells-an aggressive brain tumor-Kitambi et al. identify a potential new treatment of the disease and shed light on an unusual cell death mechanism.
Glioblastoma multiforme (GBM) kills most patients within 2 years of diagnosis. This highly invasive brain tumor escapes the reaches of the most skilled neurosurgeon and eventually resists conventional radiation and chemotherapy. In this issue of Cell, Kitambi et al. (2014) report a series of in vitro and in vivo studies that identify a potential new treatment of GBM: a compound that they term Vacquinol-1. Vacquinol-1 appears to induce an unusual form of cell death in which GBM cells engulf large amounts of extracellular fluid by macropinocytosis, leading to catastrophic vacuolization.
Like any other business, drug discovery has its fads and fashions. Before the 1980s, most drugs were discovered by observing the effect of adding different chemicals to cells in culture-so called phenotypic screens. More recently, the rapidly expanding catalog of human oncogenic mutations, coupled with difficulties in identifying the cellular targets of active compounds in phenotypic screens, has refocused drug discovery efforts on inhibitors of specific cellular proteins. This new ''target-based'' approach has enjoyed some spectacular successes (Druker et al., 2006) . But, for other cancers, including GBM, treatments that block cell signals thought to maintain the cancer (van den Bent et al., 2009) or its blood supply (Gilbert et al., 2014) have proved ineffective. The consequence has been a renaissance in phenotypic screening, fueled by the notion that targeting individual mutant proteins may be less effective than drugging the cancer phenotype that arises from a constellation of genetic and epigenetic changes (Swinney and Anthony, 2011) .
With this in mind, Kitambi et al. (2014) performed an unbiased phenotypic screen of a relatively small set of 1,364 compounds, looking for agents that altered the size or shape of GBM cells ( Figure 1 ). Several design features contributed to the success of this screen. First, the authors elected to use primary cultures of GBM cells established from two different patients, rather than long-established cell lines. In contrast to primary cultures, the phenotype and genotype of GBM cell lines are believed to diverge from the original disease, potentially muddying the results of phenotypic screens (Lee et al., 2006) . The authors then pared down the 234 ''hits'' from this initial screen through a series of in vitro assays designed to confirm anti-GBM activity (by screening against seven additional GBM primary cultures) and weed out nonspecifically toxic compounds (by counter screening against mouse embryonic stem cells and human fibroblasts). This triage included a variety of assays for cytotoxicity, apoptosis, and viability, providing important insights into compound activity and selectivity. Seventeen ''leads'' emerged from this comprehensive, in vitro screen.
To better assess the potential efficacy and unwanted toxicity of these leads, the authors turned to zebrafish. Unexpected toxicity remains a major cause of attrition in the drug development process; therefore, early and comprehensive assessment of side effects is an important consideration in drug development. Toxicological assessment of the 17 lead compounds was performed against fish embryos and ex vivo hearts (a measure of cardiovascular toxicity), whereas in vivo efficacy was measured using an innovative orthotopic model of GBM growing in fish brains. Based on these analyses, the authors selected a single compound for further study, which they named Vacquinol-1 due to its quinolone-alcohol scaffold.
Although Vacquinol-1 kills GBM cells, the authors find little evidence that this occurs through apoptosis or autophagy. Rather, by integrating various electron, live-cell imaging, and 3D microscopy techniques, they show that Vacquinol-1 induces rapid endocytic-like activity in GBM cells, leading to the formation of massive numbers of empty, variablesized, intracellular vacuoles, each bound by a single membrane; the cell membrane then ruptured, resulting in death. The report by Kitambi et al. (2014) is not the first to record this unusual form of cell death in GBM cells. In 2008, Overmeyer et al. (2008) observed a very similar process following RAS or RAC activation in GBM cells, demonstrating that the vacuoles formed are enlarged macropinosomes. They termed this death mechanism ''methuosis'' from the Greek methuo, meaning to drink to intoxication (Overmeyer et al., 2008) . Indeed, subsequent work from this same group has identified MOMIPP, an additional compound capable of inducing methuosis in GBM cells (Robinson et al., 2012) . Comparison of Vacquinol-1 and MOMIPP provides two potentially important insights for the future development of methuosisinducing drugs. First, despite inducing similar phenotypes, the pyridinyl-indole MOMIPP and quinolone-alcohol Vacquinol-1 show divergent structure-activity relationships. Whereas MOMIPP is a mostly flat molecule that does not tolerate additional steric bulk at the indole 2-position, Vacquinol-1 requires large hydrophobic bulk at the analogous position on the quinolone ring and has two stereocenters that appear to be important for activity. Second, whereas the methuosis-inducing properties of Vacquinol-1 appear to be relatively selective for GBM, MOMIPP was reported to be active against a number of cancer cell types, including GBM, breast, colon, and pancreas. Together, these data suggest that methuosis may be induced in a variety of cancers, possibly through different cellular targets.
Phenotypic screens have been criticized because of the difficulty associated with deconvoluting the cell target. Although Kitambi and colleagues do not identify the target of Vacquinol-1 precisely, they do make use of a relatively novel technology to attempt this. Using an unbiased shRNA screen that targeted over 5,000 genes, they identified an apparent requirement for MKK4 activity in Vacquinol-1-induced methuosis. These data are in keeping with observations that methuosis follows RAS-RAC activation and pinpoint this signaling system for future studies of the drug's mechanism of action (Overmeyer et al., 2008) .
Finally, to further validate Vacquinol-1 as a potential new treatment of GBM, the authors embarked on a comprehensive series of pharmacokinetic, pharmacodynamic, and efficacy studies using zebrafish and mice harboring orthotopic tumor xenografts. Of particular note, Vacquinol-1 is highly stable in vivo with a half-life in plasma of 52 hr and has excellent oral bioavailability and good brain penetration. This latter point is a particularly important feature of effective brain tumor therapies because the blood-brain barrier excludes many systemic therapies. Mice treated with oral Vacquinol-1 displayed dramatic tumor responses and significantly prolonged survival.
The study by Kitambi et al. (2014) is a true tour de force. It illustrates the value of phenotypic screening to identify drug leads, especially when coupled with appropriate chemistry, genomic technologies, and accurate in vitro and in vivo model systems. Future studies will be required to determine whether Vacquinol-1 is effective against all subtypes of GBM, if it is a useful treatment of other cancers, and the mechanistic basis of methuosis. Beginning with 1,364 compounds, the authors pursued a comprehensive series of multidisciplinary, multisystem, in vitro, and in vivo studies to identify Vacquinol-1 as an inducer of methuosis cell death and a potential new treatment of GBM.
